These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

145 related items for PubMed ID: 2741882

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Proceedings: Antipyrine, lingocaine and paracetamol metabolism in chronic liver disease.
    Forrest JA, Finlayson ND, Adjepon-Yamoah KK, Prescott LF.
    Gut; 1975 Oct; 16(10):828-9. PubMed ID: 1205294
    [No Abstract] [Full Text] [Related]

  • 3. Impairment of drug elimination in patients with liver disease.
    Narang AP, Datta DV, Mathur VS.
    Int J Clin Pharmacol Ther Toxicol; 1985 Jan; 23(1):28-32. PubMed ID: 3988389
    [Abstract] [Full Text] [Related]

  • 4. Fractional clearance of bromosulfonephthalein and metabolic clearance of antipyrine. Correlative study in liver diseases.
    Couet C, Brissot P, Messner M, Delamaire D, Gie S, Bourel M.
    Ann Gastroenterol Hepatol (Paris); 1984 Jan; 20(1):1-6. PubMed ID: 6529154
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Relationship between metabolic clearance rate of antipyrine and hepatic microsomal drug-oxidizing enzyme activities in humans without liver disease.
    Vuitton D, Miguet JP, Camelot G, Delafin C, Joanne C, Bechtel P, Gillet M, Carayon P.
    Gastroenterology; 1981 Jan; 80(1):112-8. PubMed ID: 7450397
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [Comparative study on the elimination of pindolol (visken) and antipyrin in patients with liver diseases].
    Ohnhaus EE, Münch U, Meier J.
    Schweiz Med Wochenschr; 1976 Dec 04; 106(49):1748-50. PubMed ID: 1013699
    [Abstract] [Full Text] [Related]

  • 9. [Determination of hepatic metabolic capacity: antipyrine pharmacokinetics in circulatory liver damage due to cardiac insufficiency].
    Kettner W, Banditt P, Walther H.
    Dtsch Z Verdau Stoffwechselkr; 1983 Dec 04; 43(6):255-66. PubMed ID: 6662064
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Proceedings: The influence of chronic liver disease on the elimination of d-propranolol, anti-pyrine, and indocyanine green.
    Branch RA, James JA, Read AE.
    Gut; 1974 Oct 04; 15(10):837-8. PubMed ID: 4434964
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Alteration of the pharmacokinetics and metabolism of propranolol and antipyrine elicited by indwelling catheters in the rat.
    Chindavijak B, Belpaire FM, De Smet F, Bogaert MG.
    J Pharmacol Exp Ther; 1988 Sep 04; 246(3):1075-9. PubMed ID: 3418510
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Oxidative hepatic metabolism in chronic alcoholics during the acute abstinence period: evaluation with antipyrine elimination].
    Soto Alvarez J, Alsar Ortiz MJ.
    Rev Clin Esp; 1993 Jun 04; 193(2):60-3. PubMed ID: 8341815
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Drug metabolism in patients with liver disease (author's transl)].
    Richter E, Epping J, Fuchshofen-Röckel M, Heusler H, Zilly W.
    Leber Magen Darm; 1980 Oct 04; 10(5):234-40. PubMed ID: 7464410
    [Abstract] [Full Text] [Related]

  • 18. Indocyanine green clearance following single and chronic cimetidine doses.
    MacKichan JJ, Schaal SF, Stine RA, Boudoulas H.
    Res Commun Chem Pathol Pharmacol; 1984 May 04; 44(2):323-6. PubMed ID: 6739959
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.